For the nine months ended September 30, 2026, IDEAYA Biosciences reported a net loss of $336.7 million, a significant increase from the $30.4 million loss in the prior year period, primarily due to a sharp decrease in collaboration revenue and increased R&D spending. The company strengthened its balance sheet through a follow-on public offering and warrant issuance, ending the period with approximately $1.15 billion in cash, cash equivalents, and marketable securities.
IDEAYA Biosciences reported Q3 2026 financial results, highlighting the completion of its first NDA submission for darovasertib in metastatic uveal melanoma. The company maintains a strong balance sheet with $1.15 billion in cash and equivalents, providing a projected cash runway into 2030.
Term
Q3 2026
“We are encouraged by the continued momentum at IDEAYA during the third quarter, marked by the successful completion of our first NDA filing for darovasertib in metastatic uveal melanoma. We also provided multiple clinical data updates at ESMO on darovasertib to support its potential as a foundational therapy across the entire uveal melanoma treatment journey as well as updated data from IDE849, our DLL3 TOP1 ADC, in relapsed SCLC and NEC.”